- HeartBeat.bio AG, a Vienna, Austria-based spin-off company of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), raised EUR 1.5m in seed financing
- The company intends to use the funds to establish operations, build up an experienced team over the next 12 months
- Led by Michael Krebs, CEO, HeartBeat.bio is developing a high-throughput 3D screening platform for heart diseases using self-organizing human cardiac organoids (Cardioids)
- The Cardioid technology has invented by the Mendjan lab at IMBA, a leading hub in organoid research
- The drug discovery program will focus on heart failure and cardiomyopathies as well as cardiotoxicity studies for new drug candidates
- HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with the research group of Sasha Mendjan to further develop the technology
